$MNPR

Monopar Therapeutics

Monopar Therapeutics is a clinical-stage biopharmaceutical company developing a treatment candidate for Wilson disease and radiopharmaceuticals for oncology. Its pipeline includes ALXN1840, an investigational once-daily oral drug candidate for Wilson disease, and MNPR-101-based products targeting advanced solid tumors that express uPAR. MNPR-101-Zr is being developed for cancer imaging, MNPR-101-Lu for cancer treatment, and MNPR-101-Ac is in preclinical development for treatment. Monopar conducts drug development in-house and through licensing. It is responsible for the development and commercialization of ALXN1840 under an exclusive worldwide license, and is conducting clinical trials of MNPR-101-Zr and MNPR-101-Lu in Australia. It relies on third-party contract manufacturers for its product candidates. Monopar is headquartered in Wilmette, Illinois.

No enriched coverage for $MNPR in the last 7 days.

—
$505K
Anderson Raymond
100%
See all $MNPR insider activity →

BTIG reiterates Monopar Therapeutics stock rating on NDA progress

BTIG reiterated a Buy rating and $133 price target for Monopar Therapeutics (MNPR), citing progress in its NDA submission for ALXN1840. The stock trades at $68.05, with a consensus price target range of $119-$145. Management extended its cash runway guidance to Q1 2028 and presented positive trial data. Analysts have mixed views on the stock's valuation.

H.C. Wainwright reiterates Buy rating on Monopar stock at $125

H.C. Wainwright reiterated a Buy rating and $125 price target for Monopar Therapeutics (MNPR) as it nears completion of its NDA submission for ALXN1840 in Wilson Disease. The stock trades at $68.05, with a Strong Buy consensus. Clinical data shows improvements in copper balance and neurological symptoms. The company has a strong balance sheet, with a current ratio of 33.56. BTIG raised its target to $133, while Cantor Fitzgerald downgraded to Neutral with a $119 target.

MNPR sentiment & insider activity

Recent MNPR coverage spans financial news, earnings and insider activity.

In the last 30 days, MNPR insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($505K). The most active reporter was Anderson Raymond with 4 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving MNPR

AlphAI scores every news story that mentions MNPR with an AI model for sentiment and relevance, and aggregates insider trades from Monopar Therapeutics's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MNPR

Score

H.C. Wainwright reiterates Buy rating on Monopar stock at $125

H.C. Wainwright reiterated a Buy rating and $125 price target for Monopar Therapeutics (MNPR) as it nears completion of its NDA submission for ALXN1840 in Wilson Disease. The stock trades at $68.05, with a Strong Buy consensus. Clinical data shows improvements in copper balance and neurological symptoms. The company has a strong balance sheet, with a current ratio of 33.56. BTIG raised its target to $133, while Cantor Fitzgerald downgraded to Neutral with a $119 target.

$MNPRMedEarnings

Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, November 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative t

$MNPRMedAI 8/10

Monopar presents Wilson disease trial data at liver conference

Monopar Therapeutics (MNPR) presented Phase 3 FoCus trial data for Wilson disease at a liver conference. Key findings include high rates of cirrhosis, neurologic, and psychiatric symptoms among patients. ALXN1840, its investigational therapy, showed positive long-term data. The trial is the largest randomized controlled study in Wilson disease.

$MNPRLowEarnings

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, August 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative tr

Related tickers